Login to Your Account



Isis initiates phase III study of ISIS-APOCIIIRx

By Michael Fitzhugh
Staff Writer

Thursday, August 28, 2014
Isis Pharmaceuticals Inc. initiated a six-month global phase III study of ISIS-APOCIIIRx, a triglyceride-lowering drug it plans to submit for FDA review in 2016. About 50 patients with the rare genetic condition familial chylomicronemia syndrome (FCS) will participate in the trial, which will measure as its primary endpoint percent change in fasting triglycerides from baseline at 13 weeks.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription